Taysha Gene Therapies, Inc. Increase (Decrease) in Accounts Payable
Taysha Gene Therapies, Inc. (TSHA) reported Increase (Decrease) in Accounts Payable of $5.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $4.56M, a 52.00% increase year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.29M, a 39.65% increase year-over-year.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$2.13M.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.95M.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$153.00K.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$2.92M.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$2.29M.
- Taysha Gene Therapies, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$7.80M, a 153.84% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 0 month | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.85M 10-Q · filed 2026-08-11 | $3.72M derived: sum of 3 quarters · filed 2026-08-11 | $1.77M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $1.29M 10-Q · filed 2026-05-06 | -$837.00K derived: sum of 2 quarters · filed 2026-05-06 | -$2.79M derived: sum of 3 quarters · filed 2026-05-06 | $213.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$4.07M derived: sum of 2 quarters · filed 2026-03-19 | -$1.08M derived: sum of 3 quarters · filed 2026-08-11 | -$153.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.05M derived: sum of 2 quarters · filed 2026-08-11 | $1.97M 10-Q · filed 2025-11-04 | $469.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.92M 10-Q · filed 2026-08-11 | $2.42M derived: sum of 3 quarters · filed 2026-08-11 | -$1.36M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $923.00K 10-Q · filed 2026-05-06 | -$581.00K derived: sum of 2 quarters · filed 2026-05-06 | -$4.36M derived: sum of 3 quarters · filed 2026-05-06 | -$5.98M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$5.29M derived: sum of 2 quarters · filed 2026-03-19 | -$6.90M derived: sum of 3 quarters · filed 2026-03-19 | -$2.92M 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$5.40M derived: sum of 2 quarters · filed 2025-11-04 | -$1.42M 10-Q · filed 2025-11-04 | -$2.65M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.37M 10-Q · filed 2025-08-12 | $1.14M derived: sum of 3 quarters · filed 2025-08-12 | -$2.05M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.98M 10-Q · filed 2025-05-15 | $2.75M derived: sum of 2 quarters · filed 2025-05-15 | -$438.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.33M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$4.42M derived: sum of 2 quarters · filed 2025-02-26 | -$2.65M derived: sum of 3 quarters · filed 2025-02-26 | -$2.29M 10-K · filed 2025-02-26 | |
| 2023-09-30 | -$3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.42M derived: sum of 2 quarters · filed 2024-11-13 | -$1.06M 10-Q · filed 2024-11-13 | -$5.65M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.12M 10-Q · filed 2024-08-12 | -$2.46M derived: sum of 3 quarters · filed 2024-08-12 | -$11.89M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $359.00K 10-Q · filed 2024-05-14 | -$4.23M derived: sum of 2 quarters · filed 2024-05-14 | -$13.66M derived: sum of 3 quarters · filed 2024-05-14 | -$9.99M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$14.02M derived: sum of 2 quarters · filed 2024-03-19 | -$10.35M derived: sum of 3 quarters · filed 2024-03-19 | -$7.80M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$9.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.76M derived: sum of 2 quarters · filed 2023-11-14 | -$3.22M 10-Q · filed 2023-11-14 | -$4.72M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $6.21M 10-Q · filed 2023-08-14 | $4.71M derived: sum of 3 quarters · filed 2023-08-14 | $18.32M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $2.54M 10-Q · filed 2023-05-11 | $1.04M derived: sum of 2 quarters · filed 2023-05-11 | $14.66M derived: sum of 3 quarters · filed 2023-05-11 | $15.17M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $12.11M derived: sum of 2 quarters · filed 2023-03-28 | $12.62M derived: sum of 3 quarters · filed 2023-03-28 | $14.49M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $13.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $14.13M derived: sum of 2 quarters · filed 2022-11-08 | $16.00M 10-Q · filed 2022-11-08 | $12.56M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $510.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.38M 10-Q · filed 2022-08-11 | -$1.06M derived: sum of 3 quarters · filed 2022-08-11 | $3.11M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.87M 10-Q · filed 2022-05-16 | -$1.57M derived: sum of 2 quarters · filed 2022-05-16 | $2.60M derived: sum of 3 quarters · filed 2022-05-16 | $3.83M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $724.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.96M derived: sum of 3 quarters · filed 2022-03-31 | $1.96M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.40M derived: sum of 2 quarters · filed 2021-11-10 | $5.40M 10-Q · filed 2021-11-10 | $5.40M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.24M 10-Q · filed 2021-08-16 | $1.24M derived: sum of 3 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |